Phillip Carter
Vice President, New Product Development - Cardiovascular / Hematology at Silence Therapeutics - East Palo Alto, CA, US
Phillip Carter's Colleagues at Silence Therapeutics
Stavros Giannakopoulos
Principal Scientist/ Project Leader Drug Discovery
Phillip Carter's Contact Details
650-855-9696
Chapel Hill Road,North Carolina,United States
Silence Therapeutics
Phillip Carter's Company Details
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary messenger RNAi GOLD™ Platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron loading anemias. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda, among others. For more information, please visit https://www.silence-therapeutics.com/.To view our social media guidelines, please visit: https://silence-therapeutics.com/social-media-guidelines